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Background: Even if right bundle branch block pattern or increased PR
interval duration has been earlier noted in Brugada syndrome (BS) patients,
prevalence and prognostic value of various conduction disturbances in BS
remains poorly known.
Methods: ECGs from 238 BS patients with spontaneous (n=126) or drug
induced type 1 ECG (n=112) (45±12 years old, 188 males) were reviewed.
ECG with the highest ST elevation were selected in each patient. Presence of
complete or incomplete right bundle branch block (RBBB) and of left anterior
(LAFB) or posterior (LPFB) fascicular block were evaluated according to cur-
rent guidelines for ECG interpretation. RBBB was defined by QRS > 110 or
120 ms width and S wave >40 ms in lead I. 99 patients were implanted with
an ICD. 72 patients (30%) presented an arrhythmic event defined by unex-
plained syncope (54 pts), SD (8 pts) or ICD appropriated therapies (14 pts).
Results: PR interval was 180±40 ms. 64 pts (27%) had 1st degree AV
block. AV block was not correlated to arrhythmic events but was correlated to
SCN5A mutations (66% vs 18%, p<0,0001).
62 pts (26%) had complete (56) or incomplete (6) RBBB. SCN5A muta-
tion was more often present in case of RBBB (42% vs 26%, p=0,05). ECG
with RBBB were more often recorded during pharmacological challenge (69%
vs 55%, p=0,01). Pts with RBBB had longer PR intervals (189±37 vs 174±33
ms, p=0,01). There was no correlation with HV interval, the presence of fas-
cicular blocks or degree of ST elevation.
33 pts (14%) had LAFB and 11 pts (5%) had LPFB. Fascicular blocks
were not related to PR or HV interval or RBBB. SCN5A mutation was more
often present in case of fascicular blocks (54% vs 27%, p=0,05).
There was no correlation with any arrhythmic event for the presence of
RBBB or fascicular blocks.
Conclusion: RBBB can be seen in a quarter of patients with BS, while left
anterior or posteror fascicular blocks are present in 14 and 5% respectively.
They were related to SCN5A mutations but not to arrhythmic events and could
not be used for further risk stratification.
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Background: Initially proposed in 1994, the diagnosis criteria of arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) have been recently
updated. However, diagnosis sensitivity remains poor at early stage of the dis-
ease or for familial screening. The aim of this study was to evaluate the diag-
nostic value of isoproterenol test in ARVC.
Methods: All patients referred to our institution for premature ventricular
contraction (PVC) evaluation had isoproterenol test (continuous infusion of
isoproterenol (45 to 65 μg/min) over 3 minutes, regardless of the heart rate).
Continuous 12 leads ECG, signal average ECG, holter ECG, exercise test,
echocardiogram and MRI were analysed. Isoproterenol test was considered
positive if (1) polymorphic PVC with at least one couplet (2) sustained or non
sustained ventricular tachycardia with left bundle branch morphology (but
RVOT) occurred during the test or within 10 minutes after the end of infusion.
All patients were contacted between may and july 2010. A new evaluation
was performed two years after the first one for those having a suspicion of
ARVC but didn't fulfil Task Force Criteria (TFC).
Results: 261 consecutive patients (137 men, aged 43+/–17 years) were
included in this study. Mean follow-up was 4,7+/–10,4 years (median 5 years).
The diagnosis of ARVC based on current TFC was present in 19 patients at
the initial work up and in 24 patients (17 men, aged 39+/–14 years) at the end
of the follow-up. Initial isoproterenol test was positive in 96% of the ARVC
patients and in 9% of the patient without ARVC (p<0,01). Isoproterenol test
was positive for all patients (n=5) that did not initially meet diagnosis criteria
for ARVC but subsequently developed patent form of ARVC. The sensitivity
of the isoproterenol test was 96% and the predictive positive value was 99,5%.
Conclusion: Isoproterenol test is highly sensitive (sensitivity 96%) for the
diagnosis of ARVC. This test may be used in addition to current TFC to
improve their sensibility.
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Background and aim: The new pacemaker (PM) generations featuring
extended memory functions (MF) document the occurrence of arrhythmias
over periods of several months. However, ventricular arrhythmia (VA) char-
acteristics and occurrences are less well-known in this pacemaker population.
The goal of this analysis was to evaluate the pertinence of MF at the ventric-
ular level and to describe the MF-documented VA.
Methods & Results: This analysis involved 700 pts (M 60%, F 40%, aged
76±10 yrs) implanted with single or dual chamber PM for AVB 55% or SD
45% who were seen in PM follow-up. 1438 visits were analyzed (follow-up
average at 13 months) over a period from 2 to 87 months after implantation.
Occurrences of VA are validated by EGMs, defined by at least 5 QRS com-
plexes >175/mn. The number of episodes and the duration and heart rate
during the longest arrhythmia episodes were recorded. 110 pts (16%) average
ages 75±8 yrs of whom 62% males, showed VA in 299 visits (21%). The
average number of episodes was 11 per follow-up (1-140), average duration
was 5±9 seconds (1-62 sec), and average rate was 210±28 bpm (175-295 bpm).
97% of episodes were classified as non-sustained ventricular tachycardia
(NSVT) and 3% like SVT (33-62 sec). The ejection fraction was 51±11%
(p<0.05) in the VA group compare to 57±11% in the non VA group. 64% of
VA pts shown cardiopathy compare to 45% in the non VA group (p<0.001).
Statistical analysis shown that age, pacing indication, pacing mode and cumu-
lated percentage of pacing are not relevant factors in NSVT and VT.
Conclusion: Ventricular arrhythmias are observed in 16% of pts implanted for
standard pacing indications. A major determining factor in the occurrence of
NSVT and VT is the presence of an associated cardiopathy. FMs featuring EGM
recordings are a tool for reliable diagnostic and monitoring of these events. Further
studies are required to evaluate the prognostic significance of these arrhythmias.
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Because catheter manipulation and ablation in the pericardial space is
extremely painful, most of the EP centers perform epicardial VT procedure under
general anesthesia (GA). However, GA lowers blood pressure, may interfere with
arrhythmia mapping, and use of muscle relaxants precludes identification of the
phrenic nerve. Moreover, the presence in the EP lab of an anesthesiologist is man-
datory during the whole GA. We report our experience of epicardial VT ablation
performed under conscious sedation using midazolam and sufentanyl.
Methods: All patients referred between 2006 and 2010 for epicardial VT
ablation, were scheduled to have their procedure under conscious sedation in
the absence of contraindications. Analgesia protocol included first the perfu-
sion of 1 gram of paracetamol (acetaminophen) IV and 20 mg of Nefopam IV.
Then midazolam IV was injected (bolus of 0,05 mg/kg) followed by 5 micro-
